Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial

医学 肝硬化 意向治疗分析 肝移植 随机对照试验 门脉高压 内科学 人口 外科 经颈静脉肝内门体分流术 胃肠病学 移植 环境卫生
作者
Yong Lv,Zhiping Yang,Lei Liu,Kai Li,Chuangye He,Zhenyu Wang,Wei Bai,Wengang Guo,Tianlei Yu,Xulong Yuan,Hongbo Zhang,Huahong Xie,Liping Yao,Jianhong Wang,Tao Li,Qiuhe Wang,Hui Chen,Enxin Wang,Dongdong Xia,Bohan Luo
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:4 (8): 587-598 被引量:194
标识
DOI:10.1016/s2468-1253(19)30090-1
摘要

Background The survival benefit of early placement of transjugular intrahepatic portosystemic shunts (TIPS) in patients with cirrhosis and acute variceal bleeding is controversial. We aimed to assess whether early TIPS improves survival in patients with advanced cirrhosis and acute variceal bleeding. Methods We did an investigator-initiated, open-label, randomised controlled trial at an academic hospital in China. Consecutive patients with advanced cirrhosis (Child-Pugh class B or C) and acute variceal bleeding who had been treated with vasoactive drugs plus endoscopic therapy were randomly assigned (2:1) to receive either early TIPS (done within 72 h after initial endoscopy [early TIPS group]) or standard treatment (vasoactive drugs continued to day 5, followed by propranolol plus endoscopic band ligation for the prevention of rebleeding, with TIPS as rescue therapy when needed [control group]). Randomisation was done by web-based randomisation system using a Pocock and Simon's minimisation method with Child-Pugh class (B vs C) and presence or absence of active bleeding as adjustment factors. The primary outcome was transplantation-free survival, analysed in the intention-to-treat population, excluding individuals subsequently found to be ineligible for enrolment. This study is registered with ClinicalTrials.gov, number NCT01370161, and is completed. Findings From June 26, 2011, to Sept 30, 2017, 373 patients were screened and 132 patients were randomly assigned to the early TIPS group (n=86) or to the control group (n=46). After exclusion of three individuals subsequently found to be ineligible for enrolment (two patients in the early TIPS group with non-cirrhotic portal hypertension or hepatocellular carcinoma, and one patient in the control group due to non-cirrhotic portal hypertension), 84 patients in the early TIPS group and 45 patients in the control group were included in the intention-to-treat population. 15 (18%) patients in the early TIPS group and 15 (33%) in the control group died; two (2%) patients in the early TIPS group and one (2%) in the control group underwent liver transplantation. Transplantation-free survival was higher in the early TIPS group than in the control group (hazard ratio 0·50, 95% CI 0·25–0·98; p=0·04). Transplantation-free survival at 6 weeks was 99% (95% CI 97–100) in the early TIPS group compared with 84% (75–96; absolute risk difference 15% [95% CI 5–48]; p=0·02) and at 1 year was 86% (79–94) in the early TIPS group versus 73% (62–88) in the control group (absolute risk difference 13% [95% CI 2–28]; p=0·046). There were no significant differences between the two groups in the incidence of hepatic hydrothorax (two [2%] of 84 patients in the early TIPS group vs one [2%] of 45 in the control group; p=0·96), spontaneous bacterial peritonitis (one [1%] vs three [7%]; p=0·12), hepatic encephalopathy (29 [35%] vs 16 [36%]; p=1·00), hepatorenal syndrome (four [5%] vs six [13%]; p=0·10), and hepatocellular carcinoma (four [5%] vs one [2%]; p=0·68). There was no significant difference in the number of patients who experienced other serious adverse events (ten [12%] vs 11 [24%]; p=0·07) or non-serious adverse events (21 [25%] vs 19 [42%]; p=0·05) between groups. Interpretation Early TIPS with covered stents improved transplantation-free survival in selected patients with advanced cirrhosis and acute variceal bleeding and should therefore be preferred to the current standard of care. Funding National Natural Science Foundation of China, National Key Technology R&D Program, Optimized Overall Project of Shaanxi Province, Boost Program of Xijing Hospital.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
上官若男应助Docgrace采纳,获得10
刚刚
烟花应助bobo采纳,获得10
1秒前
1秒前
Ava应助阿南采纳,获得10
1秒前
2秒前
2秒前
xy发布了新的文献求助10
2秒前
JW关闭了JW文献求助
2秒前
lll完成签到,获得积分20
3秒前
勤奋尔冬完成签到 ,获得积分10
3秒前
4秒前
ljyimu发布了新的文献求助10
4秒前
柯一一应助zhaoxuelian采纳,获得10
5秒前
舍予发布了新的文献求助10
6秒前
柯一一应助Rayoo采纳,获得10
6秒前
沛沛发布了新的文献求助10
7秒前
Simlove发布了新的文献求助10
7秒前
思源应助碧蓝丹烟采纳,获得10
7秒前
8秒前
cr发布了新的文献求助10
8秒前
水木应助王大D采纳,获得10
8秒前
对阳光过敏的非洲仔完成签到,获得积分10
8秒前
orixero应助我是张铁柱·采纳,获得10
8秒前
bobo完成签到 ,获得积分10
10秒前
ccy完成签到 ,获得积分10
10秒前
lll发布了新的文献求助10
11秒前
wu8577应助兰天采纳,获得10
11秒前
紫色奶萨发布了新的文献求助10
12秒前
健壮的怜烟应助YC采纳,获得20
12秒前
NanArtist发布了新的文献求助30
13秒前
成就的紫伊完成签到,获得积分20
14秒前
15秒前
Solarenergy发布了新的文献求助10
15秒前
zzz完成签到,获得积分10
16秒前
17秒前
司空豁发布了新的文献求助10
17秒前
cr完成签到,获得积分10
18秒前
盼盼完成签到 ,获得积分10
19秒前
李1发布了新的文献求助10
19秒前
量子星尘发布了新的文献求助10
19秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
Interpretation of Mass Spectra, Fourth Edition 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3956435
求助须知:如何正确求助?哪些是违规求助? 3502556
关于积分的说明 11108554
捐赠科研通 3233240
什么是DOI,文献DOI怎么找? 1787203
邀请新用户注册赠送积分活动 870528
科研通“疑难数据库(出版商)”最低求助积分说明 802105